Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 13/20 | 0.62 |
| ▸ | CD274 | Q9NZQ7 | 13/20 | 0.62 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.59 |
| ▸ | ATR | Q13535 | 12/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 10/20 | 0.54 |
| ▸ | ATRIP | Q8WXE1 | 10/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.52 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.52 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114867 | 0.95 | PIK3CB (0.61) | PDCD1CD274PIK3CBATRCHEK1 | |
| SCHEMBL4114870 | 0.95 | PIK3CB (0.61) | PDCD1CD274PIK3CBATRCHEK1 | |
| SCHEMBL15805508 | 0.89 | PIK3CB (0.75) | PDCD1CD274PIK3CBATRCHEK1 | |
| SCHEMBL13247081 | 0.88 | PDCD1 (0.62) | PDCD1CD274PIK3CBATRCHEK1 | |
| SCHEMBL10124233 | 0.86 | PIK3CB (0.62) | PDCD1CD274PIK3CBATRCHEK1 | |
| SCHEMBL16504198 | 0.86 | PIK3CB (0.57) | PDCD1CD274PIK3CBATRCHEK1 | |
| SCHEMBL4573169 | 0.84 | PIK3CB (0.81) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL29434923 | 0.84 | PIK3CB (0.81) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL15029392 | 0.84 | PDCD1 (0.64) | PDCD1CD274PIK3CBATRCHEK1 | |
| SCHEMBL4783458 | 0.84 | PIK3CB (0.67) | PDCD1CD274PIK3CBATRCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014090147-A1 | PYRIMIDINE DERIVATIVES AND SALTS THEREOF, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2014-06-19 | — | — | WO | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| WO-2008032036-A1 | 6-BENZIMIDAZ0LYL-2-M0RPH0LIN0-4- (AZETIDINE, PYRROLIDINE, PIPERIDINE OR AZEPINE) PYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032027-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032089-A1 | 4-BENZIMIDAZ0LYL-2-M0RPH0LIN0-6-PIPERIDIN-4-YLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032033-A1 | 4-BENZIMIDAZOLYL-2-MORPHOLINO-6-PIPERAZINYLPYRIMIDINE DERIVATIVES AS PI3K AND MTOR INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | PDCD1 403/4885CD274 893/4885PIK3CB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.